Literature DB >> 6736412

Evaluation of I.V. labetalol for treatment of posttraumatic hyperdynamic state.

D R Morel, A Forster, P M Suter.   

Abstract

A hyperdynamic state, characterized by an elevated blood pressure and tachycardia is frequently seen during the first few days following severe multiple trauma. We examined the cardiovascular effects of the alpha and beta adrenoceptor blocking agent labetalol in patients presenting a hyperdynamic cardiovascular state some days after major trauma. Ten patients with a heart rate-systolic blood pressure product (RPP) of more than 2000 during 6 consecutive hours, despite normovolaemia, adequate ventilation, analgesia and sedation were investigated. After a mean dose of 2.1 +/- 1.2 mg X kg-1 (mean +/- SD) of labetalol injected intravenously over a 10-min period, heart rate decreased from 117 +/- 28 to 102 +/- 19 beats X min-1, systolic arterial pressure from 25 +/- 3.5 to 18.5 +/- 2.7 kPa, diastolic pressure from 11 +/- 1.7 to 9.5 +/- 1.7 kPa, mean arterial blood pressure from 15.5 +/- 2.1 to 12.4 +/- 2.1 kPa, and the RPP from 2880 +/- 867 to 1853 +/- 373. The beneficial effect of this dose lasted 24 h in 8 of 10 patients without additional administration. No important side effects such as cardiac arrhythmias, hypotension, or bronchospasm were noted. We conclude that labetalol used in fractional intravenous doses permits an adequate treatment of a "hypertension-tachycardia syndrome" in severely injured patients.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6736412     DOI: 10.1007/BF00265802

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  17 in total

1.  Comparison of intravenous AH 5158 (ibidomide) and propranolol in asthma.

Authors:  C Skinner; J Gaddie; K N Palmer
Journal:  Br Med J       Date:  1975-04-12

2.  Correlations between metabolic and cardiopulmonary measurements in patients after trauma, general surgery, and sepsis.

Authors:  F B Cerra; J H Siegel; J R Border; D M Peters; R R McMenamy
Journal:  J Trauma       Date:  1979-08

3.  Interrelationship between blood pressure and regional cerebral blood flow in experimental intracranial hypertension.

Authors:  M N Shalit; S Cotev
Journal:  J Neurosurg       Date:  1974-05       Impact factor: 5.115

Review 4.  A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.

Authors:  R T Brittain; G P Levy
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

5.  Intravenous labetalol in hypertensive patients treated with beta-adrenoreceptor-blocking drugs.

Authors:  R M Pearson; C W Havard
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

6.  Plasma catecholamines in severely injured patients: a prospective study on 45 patients with multiple injuries.

Authors:  A Jäättelä; A Alho; V Avikainen; E Karaharju; J Kataja; M Lahdensuu; P Lepistö; P Rokkanen; T Tervo
Journal:  Br J Surg       Date:  1975-03       Impact factor: 6.939

7.  Early mortality and temperature regulation in burned mice following administration of catecholamines and adrenergic receptor blocking drugs.

Authors:  K Markley; E T Smallman; L W Briggs
Journal:  J Trauma       Date:  1979-07

8.  The acute and chronic hypotensive effect of labetalol and the relationship with pretreatment plasma noradrenaline levels.

Authors:  E Agabiti-Rosei; C L Alicandri; M Beschi; M Castellano; R Fariello; E Montini; M L Muiesan; G Romanelli; G Muiesan
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

9.  Metabolism of labetalol by animals and man.

Authors:  L E Martin; R Hopkins; R Bland
Journal:  Br J Clin Pharmacol       Date:  1976-08       Impact factor: 4.335

10.  Comparison of the effects of single doses of atenolol and labetalol on airways obstruction in patients with hypertension and asthma.

Authors:  S H Jackson; D G Beevers
Journal:  Br J Clin Pharmacol       Date:  1983-05       Impact factor: 4.335

View more
  2 in total

Review 1.  Labetalol. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in hypertension and ischaemic heart disease.

Authors:  K L Goa; P Benfield; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

2.  Labetalol Prevents Intestinal Dysfunction Induced by Traumatic Brain Injury.

Authors:  Yuhuang Lang; Fengming Fu; Dalong Sun; Chenhui Xi; Fengyuan Chen
Journal:  PLoS One       Date:  2015-07-17       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.